In Brief: Sepracor levalbuterol
Sepracor levalbuterol: NDA filed July 1. Data from a 362-patient four-week study show that patients on inhaled levalbuterol .63 mg generally showed a lower incidence and severity of beta-mediated side effects, such as increased pulse rate and lowered potassium levels, than did patients receiving racemic albuterol 2.5 mg...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth